6533b7d9fe1ef96bd126c2b9
RESEARCH PRODUCT
Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial.
R. HohenfellnerJens E. AltweinGünther H. JacobiR. BastingK.h. Kurthsubject
Malemedicine.medical_specialtyTime FactorsUrologyUrologyAdenocarcinomachemistry.chemical_compoundRandom AllocationBiopsymedicineHumansCyproteronePelvic lymphadenectomyDrug toxicityTestosteroneAgedClinical Trials as Topicmedicine.diagnostic_testEstradiolProstatic adenocarcinomabusiness.industryCyproterone acetateCancerProstatic NeoplasmsMiddle Agedmedicine.diseaseSurgeryCastrationchemistrybusinessdescription
Summary— Forty-two patients with previously untreated T3/4 N1-4 MO/1 prostatic adenocarcinoma were treated with either cyproterone acetate (n=21; 300 mg intramuscularly per week) or oestradiol undecylate (n=21; 100 mg intramuscularly per month) after extensive staging which included open skeletal biopsy and pelvic lymphadenectomy in some cases. Subjective and objective parameters as well as signs of drug toxicity were recorded regularly. Evaluation after 6 months showed cyproterone acetate to be more effective in the following respects: (1) the significantly different castration effect as judged by plasma testosterone, (2) the objective voiding pattern and tumour response, with regression of palpable and histologically evaluable local tumour in 16 of 21 patients, and (3) side effects and untoward reactions. Thus cyproterone acetate is suggested as a valuable alternative in the treatment of advanced prostatic cancer.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1980-06-01 | British journal of urology |